Swedish biotech SymCel has signed on a new beta-tester at an undisclosed company for its calorimetry-based live-cell screening device, its third overall beta placement and first at a commercial entity, the company's CEO told CBA News last week.

A parallel development to the increasing interest in high-content cellular-imaging has been a decidedly simpler approach to live-cell screening using label-free technology, most of which measures physical cellular characteristics to determine general cell health, and in some cases, specific compound effects.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.